| 2025-05-05 | -2.64 % |
|
| 2025-05-02 | -5.45 % |
|
| 2025-04-30 | -0.27 % |
|
| 2025-04-24 | +0.24 % |
|
| 2025-04-17 | +1.88 % |
|
| 2025-04-14 | +1.71 % |
|
| 2025-04-11 | +1.21 % |
|
| 2025-04-09 | +1.45 % |
|
| 2025-04-04 | -1.35 % |
|
| 2025-04-01 | -0.63 % |
|
| 2025-03-31 | +0.73 % |
|
| 2025-03-25 | -1.76 % |
|
| 2025-03-24 | +0.68 % |
|
| 2025-03-21 | +0.75 % |
|
| 2025-03-14 | +0.02 % |
|
| 2025-03-10 | +1.67 % |
|
| 2025-03-07 | +3.26 % |
|
| 2025-03-06 | +0.68 % |
|
| 2025-03-05 | -0.35 % |
|
| 2025-03-04 | -1.53 % |
|
| 2025-02-28 | +0.28 % |
|
| 2025-02-27 | -1.79 % |
|
| 2025-02-26 | -1.33 % |
|
| 2025-02-19 | +0.42 % |
|
| 2025-02-18 | +1.09 % |
|
| 2025-02-12 | -1.46 % |
|
| 2025-02-11 | -1.18 % |
|
| 2025-02-06 | -10.1 % |
|
| 2025-02-05 | +1.7 % |
|
| 2025-02-04 | -0.2 % |
|
| 2025-02-03 | -0.58 % |
|
| 2025-01-28 | -1.35 % |
|
| 2025-01-24 | +0.45 % |
- The article does not provide specific information about Hologic (HOLX) stock, but it mentions that the stock was up 0.45%. Hologic's stock may have risen due to positive market trends, favorable earnings reports, or investor sentiment, though the article focuses mainly on Abbott Laboratories (ABT) and its recent activities.
- The article mentions that Hologic (HOLX) stock was up 0.45%, but it primarily discusses Representative Thomas H. Kean, Jr.'s purchase of shares in Pernod Ricard SA, with no direct explanation for Hologic's stock increase. The rise in Hologic's stock could be attributed to favorable market conditions, positive earnings expectations, or industry trends, but the article does not provide specific reasons.
- The article discusses the recent trading activity of Representative Thomas H. Kean, Jr., particularly regarding his purchase of Analog Devices stock, but it does not directly mention Hologic (HOLX). However, Hologic's stock is noted to have increased by 0.45% last night, likely due to overall positive market sentiment or favorable financial results impacting investor confidence.
- Hologic (HOLX) stock rose 0.45% amid mixed analyst revisions on EPS estimates, with some maintaining "outperform" ratings and a general consensus of "Moderate Buy."
The stock likely increased due to this supportive analyst sentiment and recent institutional investors' interest, which reflects confidence in the company's performance despite slight downgrades in earnings expectations.
|
| 2025-01-23 | -0.69 % |
|
| 2025-01-16 | +1.77 % |
|
| 2025-01-14 | -0.13 % |
|
| 2025-01-10 | -1.43 % |
|
| 2025-01-07 | -1.46 % |
|
| 2025-01-06 | +0.79 % |
|
| 2024-12-18 | -1.09 % |
|
| 2024-12-17 | -0.25 % |
|
| 2024-12-12 | -0.58 % |
|
| 2024-12-09 | +0.6 % |
|
| 2024-12-05 | -1.13 % |
|
| 2024-11-26 | -0.92 % |
|
| 2024-11-25 | +0.96 % |
|
| 2024-11-21 | +0.87 % |
|
| 2024-11-19 | -0.28 % |
|
| 2024-11-15 | +1.37 % |
|
| 2024-11-12 | +0.47 % |
|
| 2024-11-11 | +0.8 % |
|
| 2024-11-08 | -0.67 % |
|
| 2024-11-07 | -1.49 % |
|
